Behavioral
Russellville Holdings LLC
Russellville Holdings LLC was paid $6.44M by Medicaid between Jan 2018 and Dec 2024, across 189 billing codes. Its largest line is 0241U, Neonatal screening for hereditary disorders, genomic sequence analysis panel — 8.8% of everything it billed.
33Billing provider infoRUSSELLVILLE HOLDINGS LLC
RUSSELLVILLE, AR 72801
RUSSELLVILLE, AR 72801
33aNPI1033160049assigned 05/14/2006
33bProvider typeSocial Worker
28Total paid$6.44M
24GClaims354,625
24DCodes billed189
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Social Worker providers in Arkansas
Rank by total paid#1 of 10
Median peer was paid$11K
This provider vs. median581×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official LAWRENCE, CHARLOTTE controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 52,834 | $707K | |
| 2019 | 58,910 | $941K | |
| 2020 | 45,550 | $839K | |
| 2021 | 47,903 | $822K | |
| 2022 | 52,951 | $1.07M | |
| 2023 | 54,407 | $1.18M | |
| 2024incomplete | 42,070 | $880K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 8.8% | 6,403 | 5,576 | $568K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 7.5% | 4,311 | 3,668 | $482K |
| 70450 | Computed tomography, head or brain; without contrast material | 6.4% | 5,087 | 4,222 | $409K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 5.6% | 4,519 | 3,640 | $363K |
| 80048 | Basic metabolic panel (calcium, ionized) | 3.8% | 20,277 | 14,649 | $243K |
| 87631 | 3.6% | 3,044 | 2,780 | $233K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 3.5% | 9,315 | 2,227 | $227K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 3.4% | 4,290 | 3,462 | $221K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | 3.3% | 1,931 | 1,617 | $214K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 3.3% | 37,885 | 26,832 | $210K |
| 72125 | Computed tomography, cervical spine; without contrast material | 3.0% | 1,809 | 1,531 | $196K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 2.5% | 2,385 | 1,908 | $163K |
177 more codes
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | 2.5% | 2,148 | $158K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | 2.3% | 732 | $146K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 2.2% | 3,225 | $144K |
| 99283 | Emergency room visit (moderate) | 2.1% | 3,197 | $137K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | 2.1% | 591 | $135K |
| 80053 | Comprehensive metabolic panel | 2.0% | 10,947 | $128K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.9% | 2,073 | $121K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.7% | 13,473 | $107K |
| 99284 | Emergency room visit (serious) | 1.4% | 4,232 | $88K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | 1.3% | 449 | $85K |
| 99285 | Emergency room visit (most serious) | 1.3% | 3,316 | $83K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 1.1% | 2,022 | $71K |
| 71045 | Radiologic examination, chest; single view | <1% | 10,424 | $61K |
| 84484 | <1% | 9,420 | $58K | |
| 83690 | <1% | 7,428 | $52K | |
| 80076 | <1% | 6,714 | $44K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 12,029 | $43K |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 2,140 | $43K |
| 81025 | <1% | 6,163 | $43K | |
| 86901 | <1% | 2,222 | $41K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 3,025 | $40K |
| 85730 | <1% | 9,648 | $40K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 5,552 | $37K |
| 97161 | <1% | 859 | $36K | |
| 81002 | <1% | 13,795 | $35K | |
| 83880 | <1% | 2,327 | $35K | |
| 80047 | <1% | 1,887 | $33K | |
| 82150 | <1% | 5,722 | $31K | |
| 93017 | <1% | 2,589 | $30K | |
| 85610 | <1% | 11,001 | $30K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,966 | $27K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,053 | $25K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 874 | $23K |
| 82803 | <1% | 1,644 | $21K | |
| 87040 | <1% | 1,813 | $20K | |
| 82962 | <1% | 5,054 | $18K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,184 | $18K |
| 72141 | <1% | 98 | $18K | |
| 80320 | <1% | 1,518 | $18K | |
| 73630 | <1% | 773 | $17K | |
| 86850 | <1% | 1,721 | $16K | |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 77 | $16K |
| 87077 | <1% | 2,413 | $16K | |
| 83605 | <1% | 2,304 | $15K | |
| 80061 | Lipid panel | <1% | 2,217 | $14K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,467 | $14K |
| 73030 | <1% | 1,119 | $14K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 501 | $14K |
| 81000 | <1% | 5,039 | $14K | |
| 73610 | <1% | 842 | $13K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 81 | $13K |
| 82607 | <1% | 636 | $13K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,780 | $12K |
| 82746 | <1% | 621 | $12K | |
| 88720 | <1% | 1,921 | $12K | |
| 73221 | <1% | 45 | $12K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 886 | $12K |
| 80050 | General health panel | <1% | 232 | $11K |
| 73502 | <1% | 961 | $11K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 218 | $10K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,093 | $10K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,782 | $10K |
| 76830 | Ultrasound, transvaginal | <1% | 212 | $10K |
| 93971 | <1% | 394 | $10K | |
| 82550 | <1% | 1,633 | $9K | |
| 82553 | <1% | 1,505 | $9K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 228 | $9K |
| 73130 | <1% | 482 | $9K | |
| 87186 | <1% | 2,197 | $9K | |
| 93226 | <1% | 364 | $8K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 199 | $8K |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 374 | $7K |
| 73562 | <1% | 395 | $7K | |
| 84145 | <1% | 668 | $7K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 6,208 | $7K |
| 72100 | <1% | 403 | $7K | |
| 74018 | <1% | 380 | $6K | |
| 73560 | <1% | 466 | $6K | |
| 36600 | <1% | 579 | $6K | |
| 80329 | <1% | 392 | $6K | |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | <1% | 17 | $6K |
| 84703 | <1% | 676 | $6K | |
| 93458 | <1% | 164 | $6K | |
| 93225 | <1% | 364 | $6K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 74 | $6K |
| 94060 | <1% | 563 | $5K | |
| 83735 | <1% | 1,692 | $5K | |
| 84702 | <1% | 599 | $5K | |
| 86900 | <1% | 2,267 | $5K | |
| 73110 | <1% | 224 | $4K | |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 12 | $4K |
| 87070 | <1% | 539 | $4K | |
| 85379 | <1% | 596 | $4K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 716 | $4K |
| 76770 | <1% | 158 | $4K | |
| 86592 | <1% | 601 | $4K | |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 470 | $4K |
| 90715 | <1% | 194 | $3K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 14 | $3K |
| 95811 | <1% | 33 | $3K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 103 | $3K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 30 | $3K |
| 82565 | <1% | 576 | $3K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 30 | $3K |
| 70486 | <1% | 34 | $3K | |
| 72040 | <1% | 157 | $2K | |
| 70498 | <1% | 30 | $2K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 210 | $2K |
| 94727 | <1% | 286 | $2K | |
| J0153 | Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) | <1% | 245 | $2K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 297 | $2K |
| 71250 | <1% | 31 | $2K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 78 | $2K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 355 | $2K |
| 76536 | <1% | 41 | $1K | |
| 94664 | <1% | 307 | $1K | |
| 70496 | <1% | 18 | $1K | |
| 72070 | <1% | 93 | $1K | |
| 71271 | <1% | 29 | $1K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 30 | $1K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 16 | $1K |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 337 | $1K |
| J3490 | Unclassified drugs | <1% | 1,594 | $943.21 |
| 72131 | <1% | 31 | $860.00 | |
| 97165 | <1% | 16 | $833.89 | |
| 72110 | <1% | 63 | $830.50 | |
| 82728 | <1% | 174 | $677.48 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,946 | $664.27 |
| 86140 | <1% | 148 | $642.44 | |
| 96376 | <1% | 173 | $618.72 | |
| 84439 | <1% | 42 | $575.15 | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 189 | $532.98 |
| 93970 | <1% | 31 | $515.77 | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 20 | $480.45 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 945 | $474.67 |
| 77066 | Tomosynthesis, mammo | <1% | 12 | $453.84 |
| 74022 | <1% | 19 | $424.64 | |
| 73090 | <1% | 28 | $415.29 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 26 | $373.17 |
| 71020 | <1% | 137 | $301.00 | |
| 83615 | <1% | 160 | $298.57 | |
| 87210 | <1% | 59 | $282.25 | |
| 81001 | <1% | 114 | $281.87 | |
| 76642 | <1% | 15 | $274.94 | |
| 82570 | <1% | 65 | $265.49 | |
| A9270 | Non-covered item or service | <1% | 4,679 | $262.19 |
| 84156 | <1% | 66 | $199.10 | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 16 | $189.02 |
| 73070 | <1% | 14 | $162.00 | |
| 93242 | <1% | 31 | $151.89 | |
| 72050 | <1% | 17 | $144.52 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 67 | $138.87 |
| G0378 | Hospital observation service, per hour | <1% | 154 | $138.37 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 15 | $95.34 |
| 85651 | <1% | 43 | $86.19 | |
| 71010 | <1% | 307 | $85.01 | |
| 82272 | <1% | 34 | $84.47 | |
| 97014 | <1% | 288 | $80.68 | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 12 | $77.63 |
| 85347 | <1% | 44 | $45.68 | |
| 84132 | <1% | 46 | $34.69 | |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 36 | $22.95 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 136 | $22.09 |
| 84100 | <1% | 20 | $13.56 | |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 16 | $4.50 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 0% | 3,803 | $0.00 |
| D2929 | 0% | 64 | $0.00 | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | 0% | 163 | $0.00 |
| 99152 | 0% | 180 | $0.00 | |
| J1644 | Injection, heparin sodium, per 1000 units | 0% | 12 | $0.00 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | 0% | 133 | $0.00 |
| D3220 | Therapeutic pulpotomy (excluding final restoration) - removal of pulp coronal to the dentinocemental junction | 0% | 81 | $0.00 |
| D7140 | Extraction, erupted tooth or exposed root | 0% | 13 | $0.00 |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 0% | 87 | $0.00 |
| G0379 | Direct admission of patient for hospital observation care | 0% | 13 | $0.00 |
| 99153 | Mod sedat endo service >5yrs | 0% | 69 | $0.00 |
| 97035 | 0% | 35 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLAWRENCE, CHARLOTTE (SECRETARY)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.